Loading...
•
Mar 31, 2023
Lianbio-Adr Q1 2023 Earnings Report
LianBio reported financial results for the first quarter ended March 31, 2023.
Key Takeaways
LianBio reported a net loss of $24.0 million for the first quarter of 2023, compared to a net loss of $27.7 million for the first quarter of 2022. The company's cash, cash equivalents, marketable securities and restricted cash totaled $286.6 million as of March 31, 2023, and is projected to fund operations through the end of 2024. The company is preparing for the commercial launch of mavacamten in China.
Phase 3 trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) met primary endpoint.
China National Medical Products Administration (NMPA) accepted mavacamten New Drug Application (NDA) with priority review.
Mavacamten commercial launch preparations continue in China, supported by the promotion of Pascal Qian to Chief Commercial Official.
Cash, cash equivalents and marketable securities of $286.5 million with runway through the end of 2024.
Forward Guidance
LianBio projects its current cash, cash equivalents, marketable securities, and restricted cash will be sufficient to fund its current operating plan through the end of 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...